Skip to content

Netherlands Heart Foundation's Myocardial INfarction and Depression-Intervention Trial: effects of antidepressant treatment following myocardial infarction

Effects of antidepressant treatment following myocardial infarction: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN57865866
Enrollment
331
Registered
2012-05-22
Start date
2000-05-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction and depression Circulatory System Acute myocardial infarction

Interventions

Patients in the intervention arm were offered several treatment options according to a strictly defined protocol: First-choice treatment was double-blind placebo-controlled treatment with the selecti

Sponsors

The Netherlands Heart Foundation (Netherlands)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Hospital admission for myocardial infarction, defined as: Documentation of an increase in cardiac enzymes and either electrocardiographic changes and/or chest pain (Enzyme changes: elevation of creatine kinase isoenzyme (CK-MB) (CK-MB _1_ ULN and CK-MB/CK ratio above the local normal limit) or in case CKMB is not available, elevation of total CK (total CK _2 _ ULN); electrocardiographic changes: new significant Q waves in at least 2 out of 12 leads or new R in V1 with R/S ratio _1; Chest pain: _20 minutes of new or markedly increased chest pain) 2. Age more than or equal to18 years 3. Signed informed consent for study

Exclusion criteria

Exclusion criteria: 1. Occurrence of MI while the patient was hospitalized for another reason, except for unstable angina pectoris 2. Lacking capability to participate in study procedures (ie, patients notable to communicate and patients not available for follow-up) 3. Any disease likely to influence short-term survival 4. Already receiving psychiatric treatment for depression 5. Participation in any clinical trial that might intervene with the study objectives and/or safety of the patient

Design outcomes

Primary

MeasureTime frame
The occurrence of any significant cardiac event. Cardiac events included: 1. Cardiac death or hospital admission for documented non-fatal myocardial infarction 2. Myocardial ischaemia 3. Coronary revascularisation (coronary angioplasty or bypass surgery) 4. Heart failure or ventricular tachycardia occurring in the time between randomisation and 18 months postmyocardial infarction

Secondary

MeasureTime frame
Other cardiac-related hospital admissions (defined as admissions with an initial evaluation by a cardiologist or hospitalisations at the cardiology ward)

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026